Email page to a friendBookmark this page
tufts.edu
    Home  
 
  Research Agenda  >  Impact Reports  >  Search Results
 
 
 
Show      
Page: 1 of 70       Go To Page
 
RS 2922
Kaitin KI, editor.  Best practices of top pharma/biotech performers  Tufts Center for the Study of Drug Development R&D Management Report 2009 Oct;4(4)**
RS 2921
Kaitin KI, editor.  Market exclusivity for first–in–class drugs has shortened to 2.5 years  Tufts Center for the Study of Drug Development Impact Report 2009 Sep/Oct;11(5)**
RS 2920
Reichert JM.  Probabilities of success for antibody therapeutics  mAbs 2009;1(4):387-9
Click here for a full-text version. This is an Adobe Acrobat file. Click here if you need Adobe Acrobat software. It is free.
RS 2919
Milne C-P Tait J.  Evolution along the government–governance continiuum: impacts of regulation on medicines innovation in the United States. Chapter 5 in: The limits to governance: the challenge of policy–making for the new life sciences. Edited by Lyall C Papaioannou T Smith , Burlington VT, Ashgate, 2009:107-132**
RS 2918
Milne C-P.  Pharmaceutical economics and applications to pediatrics: business case development. Chapter 5 in: Pediatric drug developmen : concepts and applications, [edited by] Mulberg A Silber S van den Anker , Hoboken NJ, Wiley, 2008:39-57**
RS 2917
Milne C-P.  Population dynamics, demographics, and disease burden in infants and children across the world. Chapter 4 in: Pediatric drug development : concepts and applications, [edited by] Mulberg A Silber S van den Anker J, Hoboken NJ, Wiley, 2008:21-38**
RS 2916
Getz KA Zuckerman R DiMasi JA Kaitin KI.  Drug development portfolio and spending practices after mergers and acquisitions  Drug Information Journal 2009;43(4):493-500 http://www.nxtbook.com/nxtbooks/dia/druginformationjournal0709/#/118
RS 2915
Cohen J.  Market access in the wake of NICE: biopharma’s friend or foe?  European Pharmaceutical Review 2009 #48:8-12
Click here for a full-text version. This is an Adobe Acrobat file. Click here if you need Adobe Acrobat software. It is free.
RS 2914
Cohen J Wilson A Faden L.  Off–label use reimbursement  Food and Drug Law Journal 2009;64(2):391-403
RS 2912
Kaitin KI, editor.  Moving drug development outsourcing to a higher level  Tufts Center for the Study of Drug Development R&D Management Report 2009 Jun;4(3)**
 
Page: 1 of 70   
 
  (Reprints are free, see directions below)
 
* This publication is not available from the Center. Please contact a library or the publisher.
** This publication is for sale at our website http://csdd.tufts.edu/InfoServices/Order.pdf
 
 

To request an article reprint:

  • Select the checkboxes of any articles you are interested in
    (you may page through the results and check as many checkboxes as you would like before clicking "Send Reprint").
  • Click on "Send Reprint" when searching the bibliography.
  • Fill out the information on the Reprint Request Form and submit it.
Or
  • Contact our research librarian, Peg Hewitt, by phone at 617-636-2185.
  • Or email to peg.hewitt@tufts.edu.
  • To speed your request, please provide the Tufts Center RS reference number for the reprints you desire.

 


Back


Home - About Us - CSDD Institute - Information Services - Research - Publications - News & Events - Links - Contact Us - Site Map
Copyright © 2009 Tufts Center for the Study of Drug Development. All Rights Reserved.
Site Last Updated: June 19, 2009
Download Adobe Acrobat   Bookmark Page   Send this page